In a related editorial, the authors note that this new formulation of buprenorphine depot clearly minimises the risk of buprenorphine diversion. “In some countries, precautions include restrictions on take-home dosing and required observed dosing in the clinic or at a pharmacy. In US office-based practice, guidelines recommend minimising prescribed doses and quantities, and doing regular or random pill counts if diversion is of particular concern. These adherence and diversion risk mitigation strategies have economic and psychological costs; prolonged use of such restrictions can result in an antagonistic interaction pattern between patient and provider”, and this new formulation offers an advantage in this scenario.